Welcome to our dedicated page for Ginkgo Bioworks Holdings SEC filings (Ticker: DNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ginkgo Bioworks’ synthetic biology foundry files dense reports that mix government biosecurity contracts, milestone-based collaboration revenue, and intricate share-based compensation tables—information that can overwhelm even seasoned analysts. If you have ever searched for “Ginkgo Bioworks insider trading Form 4 transactions” or wondered how to decode a 300-page 10-K, you know the challenge.
Stock Titan solves that problem. Our platform pulls every filing—10-K, 10-Q, 8-K, S-1, DEF 14A and more—directly from EDGAR, then applies AI-powered summaries that turn jargon into plain English. Need the Ginkgo Bioworks quarterly earnings report 10-Q filing? We highlight Foundry capacity metrics and Cell Engineering backlog in seconds. Tracking management moves? Receive Ginkgo Bioworks Form 4 insider transactions real-time, complete with context so you can spot trends before they hit the headlines.
Use cases investors rely on daily:
- Compare Biosecurity and Cell Engineering revenue in the latest Ginkgo Bioworks annual report 10-K simplified.
- Monitor Ginkgo Bioworks executive stock transactions Form 4 alongside option grant details in the proxy statement executive compensation.
- See contract awards and lab expansions inside Ginkgo Bioworks 8-K material events explained.
- Dive deeper with Ginkgo Bioworks earnings report filing analysis generated by our AI.
Whether you’re understanding Ginkgo Bioworks SEC documents with AI for the first time or refining a valuation model, Stock Titan’s real-time updates and expert commentary keep you ahead without wading through technical appendices.
Ginkgo Bioworks Holdings, Inc. reported a leadership transition in its operating roles. Effective January 1, 2026, co‑founder Dr. Reshma Shetty will transition her Chief Operating Officer responsibilities to Chief Executive Officer Dr. Jason Kelly and executive Jennifer Wipf. Dr. Shetty will remain President, continue serving on the Board of Directors, and focus on expanding and using the company’s autonomous lab to deliver cell engineering service offerings, while Dr. Kelly will take on the principal operating officer policymaking duties.
Jennifer Wipf, previously Chief Commercial Officer and General Manager, Discovery Solutions and Manufacturing, will oversee operations functions such as day‑to‑day commercial operations, procurement, deployment, facilities and real estate, and people operations, reporting to Dr. Kelly. The changes keep Dr. Shetty in a substantial policymaking role while formalizing broader operating responsibilities for Dr. Kelly and Ms. Wipf.
Ginkgo Bioworks Holdings, Inc. reported insider equity transactions by a senior officer. On 12/12/2025, restricted stock units vested and were converted into 1,174 and 312 shares of Class A common stock, reflecting ongoing equity compensation. After these conversions, the officer directly held 8,224 Class A shares.
On 12/15/2025, 736 Class A shares were sold at $8.886 per share to satisfy tax withholding obligations tied to the vesting of restricted stock and restricted stock units. The company’s equity incentive plans allow these mandatory “sell to cover” transactions, which are described as non‑discretionary for the officer. Following the sale, the officer directly owned 7,488 Class A shares and continued to hold restricted stock units subject to multi‑year vesting schedules beginning May 1, 2024.
Steve Coen filed a notice of proposed sale of restricted stock for the company with ticker DNA. The filing covers a planned sale of 736 Class A shares through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 12/15/2025 and an aggregate market value of $6540.02. The table lists 48523595 Class A shares outstanding.
The shares to be sold were acquired on 12/12/2025 via restricted stock vesting from the issuer as compensation. The notice also reports that in the prior three months Steve Coen sold 5609 and 1312 Class A shares on 10/01/2025 and 10/17/2025, generating gross proceeds of $84135.00 and $17907.89. By signing, the seller represents he does not know any material adverse information about the issuer’s current and prospective operations that has not been publicly disclosed and acknowledges potential federal criminal penalties for intentional misstatements.
Ginkgo Bioworks insider plans another small Class A share sale. A holder has filed a notice to sell 2,200 shares of Class A common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $20,988.00. The filing lists 48,523,595 Class A shares outstanding.
The seller, identified as Austin Che, acquired these shares through restricted stock vesting in October 2022 as compensation from the issuer. Over the past three months, the same seller reported three separate NYSE sales of 2,200 Class A shares each, with gross proceeds of $23,716.00, $33,462.00, and $18,700.00. The notice also includes a representation that the seller is not aware of undisclosed material adverse information about the company’s current or prospective operations.
Ginkgo Bioworks Holdings, Inc.: Cascade Investment, L.L.C. and William H. Gates III reported beneficial ownership of 3,621,636 Class A shares, representing 7.5% of the class. William H. Gates III may be deemed to beneficially own these shares as the sole member of Cascade. The filing date of event is 09/30/2025.
The reported amount includes 299,052 earn-out shares that vest in equal tranches if the stock trades at specified price thresholds for 20 of 30 consecutive trading days before September 16, 2026, as outlined in the merger agreement. The holders report sole voting and dispositive power over 3,621,636 shares and no shared power. The percentage is based on 48,523,595 shares outstanding as of October 31, 2025. The certification states the securities are not held to change or influence control.
Form 144 filing: A stockholder filed notice to sell up to 2,200 shares of Class A common stock through Fidelity Brokerage Services, with an aggregate market value of $18,700, on or about 11/12/2025 on the NYSE.
The shares were acquired on 10/18/2022 via restricted stock vesting from the issuer as compensation. In the past three months, the filer (Austin Che) reported sales of 2,200 shares on 09/10/2025 for gross proceeds of $23,716 and 2,200 shares on 10/08/2025 for gross proceeds of $33,462. Shares outstanding were 48,523,595.
Ginkgo Bioworks (DNA) reported a smaller third quarter with a wider loss. Total revenue was $38.8 million, led by Cell Engineering at $29.4 million and Biosecurity at $9.5 million. The company recorded a net loss of $80.8 million and basic EPS of $1.45 loss, reflecting lower revenue and ongoing operating costs.
Liquidity shifted into marketable securities during 2025: cash and cash equivalents were $111.1 million and marketable securities were $350.8 million as of September 30, 2025. Net cash used in operating activities was $123.4 million for the nine months. Stockholders’ equity was $559.8 million.
Ginkgo launched a $100.0 million at‑the‑market program on September 4, 2025 and issued 975,300 Class A shares for $9.4 million in net proceeds. The restructuring begun in 2024 continued, with $10.7 million in year‑to‑date charges and expected workforce reduction costs of $28.0–$30.0 million. An amended Google Cloud agreement reset annual minimums and included a $21.4 million shortfall accrued and a one‑time $14.0 million payment in Q4 2025. As of October 31, 2025, shares outstanding were 48,523,595 Class A, 9,066,624 Class B, and 3,000,000 Class C.
Ginkgo Bioworks (DNA)
The filing, dated November 6, 2025, is an administrative disclosure under Item 2.02 (Results of Operations and Financial Condition) and includes the Inline XBRL cover page file as Exhibit 104.
Ginkgo Bioworks (DNA) filed a Form 4 for its CFO showing routine equity activity tied to RSU vesting. On 10/16/2025, restricted stock units were converted to Class A shares via code M in three tranches: 1,174 shares, 312 shares, and 1,061 shares.
On 10/17/2025, the CFO sold 1,312 shares at $13.649 per share under code S to cover tax withholding related to these vestings, as permitted by the company’s equity plans. Following the transactions, the CFO directly beneficially owned 6,738 Class A shares.
DNA filed a Form 144 notice for a proposed sale of 5,609 Class A shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 84,135. The approximate sale date listed is 10/21/2025.
The shares were acquired via restricted stock vesting as compensation on multiple dates in 2024, including 4,062 shares on 05/01/2024 and smaller vestings thereafter, totaling the amount to be sold. The filing lists 47,089,598 shares outstanding for the class. The section on recent activity shows a prior sale of 310 shares on 08/22/2025 for gross proceeds of 3,842.79.
FAQ
What is the current stock price of Ginkgo Bioworks Holdings (DNA)?
What is the market cap of Ginkgo Bioworks Holdings (DNA)?
